文献速递类风湿关节炎

初始治疗策略与进展为难治性类风湿关节炎的关联:20年真实世界队列证据

Association between initial treatment strategy and progression to difficult-to-treat rheumatoid arthritis (D2T-RA): evidence from a 20-year-old real-world cohort.
PubMed 文献 · RMD Open · 2026-09-23

该回顾性队列纳入675例确诊类风湿关节炎患者,平均随访217.1±131.16个月,126例(18.7%)符合难治性RA(D2T-RA)标准。在2000年后亚组(498例)中,初始使用TNFi与非TNFi、或TNFi循环与其他作用机制转换策略之间,D2T-RA风险无显著差异;糖皮质激素暴露与风险升高独立相关(HR 2.47,95%CI 1.38至4.42),延迟启动b/tsDMARD与风险降低相关(HR 0.990,95%CI 0.98至0.996)。

要点

  • 初始b/tsDMARD作用机制选择与D2T-RA进展风险无显著关联。
  • 糖皮质激素暴露与D2T-RA风险升高独立相关(HR 2.47)。
  • 延迟启动b/tsDMARD与D2T-RA风险降低相关(HR 0.990)。

核心结论

  • 在该观察性队列中,初始作用机制选择与D2T-RA进展无关联,疾病严重度标志似比治疗策略更突出地驱动难治性演变。

研究设计与样本

  • 回顾性分析675例确诊类风湿关节炎患者,从首次就诊追踪至所有b/tsDMARD治疗线及末次随访或D2T-RA分类,采用Kaplan-Meier、log-rank和多因素Cox回归分析。

主要发现

  • 675例患者平均随访217.1±131.16个月,126例(18.7%)符合D2T-RA标准。
  • TNFi占一线和二线治疗的大多数(81.0%和53.2%)。
  • 2000年后亚组(498例)中,TNFi与非TNFi起始者之间、TNFi循环与其他作用机制转换策略之间D2T-RA风险均无显著差异。
  • 糖皮质激素暴露与D2T-RA风险升高独立相关(HR 2.47,95%CI 1.38至4.42)。
  • 延迟启动b/tsDMARD与D2T-RA风险降低相关(HR 0.990,95%CI 0.98至0.996)。

临床怎么用

  • 初始b/tsDMARD作用机制选择可能不影响D2T-RA进展风险,疾病严重度标志更值得关注。
  • 应重视糖皮质激素暴露与D2T-RA风险的关联,并评估延迟启动b/tsDMARD对风险的影响。
  • 上述发现需在前瞻性或随机化 setting 中验证后方可转化至临床实践。

局限性

  • 为观察性回顾性队列,需前瞻性或随机化研究验证后方可转化至临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/OBJECTIVES: Despite major advances in rheumatoid arthritis (RA) management, a substantial proportion of patients evolve to difficult-to-treat RA (D2T-RA). We estimated the probability of progression to D2T-RA and assessed whether the initial choice of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is associated with this risk. METHODS: We retrospectively analysed 675 patients with established RA from the first consultation through all b/tsDMARD lines to the last follow-up or D2T-RA classification. Kaplan-Meier, log-rank and multivariable Cox regression analyses were performed to identify factors associated with D2T-RA progression. RESULTS: Of the 675 patients (mean follow-up of 217.1±131.16 months), 126 (18.7%) fulfilled the D2T-RA criteria. Tumour necrosis factor inhibitor (TNFi) accounted for most first-line and second-line treatments (81.0% and 53.2%). In the post-2000 subcohort (498 patients), no significant difference in D2T-RA risk was observed between TNFi and non-TNFi starters nor between TNFi-cycling or other mechanism of action (MoA)-switching strategies. Glucocorticoid exposure was independently associated with increased risk (HR 2.47, 95% CI 1.38 to 4.42) and delayed b/tsDMARD initiation with decreased hazard (HR 0.990, 95% CI 0.98 to 0.996). CONCLUSION: In this observational cohort, initial MoA choice was not associated with D2T-RA progression. Disease severity markers appeared more prominent than treatment strategies in driving refractory evolution. Validation in a prospective/randomised setting is required before potential transition into clinical practice.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Van Mullem C, Natalucci F, Avramovska A, et al. Association between initial treatment strategy and progression to difficult-to-treat rheumatoid arthritis (D2T-RA): evidence from a 20-year-old real-world cohort. RMD Open. 2026. PMID: 42778329. doi:10.1136/rmdopen-2026-007098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。